If approved, Tecentriq will be the first and only cancer immunotherapy available for certain people with early-stage NSCLC in Europe
Selvax's goal is to develop safe, effective and immunological-based treatments for a range of hard-to-treat solid tumours
The large-scale production of PhytoChol in Hanau, Germany, will meet an increased market demand for cholesterol
Senior R&D leader from Pfizer and bluebird bio to support Strand’s platform of programmable mRNA-based therapeutics
The company will manufacture a cancer immunotherapy product from 2022
Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant setting
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
